Honokiol inhibits lung tumorigenesis through inhibition of mitochondrial function

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Honokiol, a bioactive compound from Magnolia bark, exhibits anti-tumor properties.
• Existing research shows honokiol inhibits various cancer types in vitro and in vivo.
• A more relevant model is needed to fully assess honokiol's chemopreventive potential for lung cancer.

Purpose of the Study:

• To investigate the chemopreventive efficacy of honokiol in an N-nitroso-trischloroethylurea (NTCU)-induced lung squamous cell carcinoma (SCC) initiation model.
• To explore the underlying mechanisms of honokiol's action against lung SCC.

Main Methods:

• Utilized an NTCU-induced lung SCC initiation model in mice.
• Administered honokiol and assessed histological changes in bronchial tissues.
• Performed P63 staining to confirm SCC phenotype.
• Conducted in vitro studies on lung SCC cells to analyze proliferation, cell cycle, and apoptosis.
• Investigated the impact of honokiol on mitochondrial respiration and redox status.

Main Results:

• Honokiol significantly reduced the percentage of abnormal lung SCC histology (from 24.4% to 11.0%, P=0.01).
• Honokiol increased the presence of normal bronchial histology (from 20.5% to 38.5%, P=0.004).
• In vitro, honokiol inhibited SCC cell proliferation, induced G1-S cell cycle arrest, and promoted apoptosis.
• Honokiol was found to interfere with mitochondrial respiration, altering mitochondrial redox status and triggering apoptosis.

Conclusions:

• Honokiol demonstrates significant chemopreventive efficacy against lung SCC in a relevant animal model.
• Honokiol inhibits lung SCC progression through mechanisms including cell cycle arrest, apoptosis induction, and modulation of mitochondrial respiration.
• Targeting mitochondrial respiration represents a novel mechanism for honokiol's anti-lung SCC activity, positioning it as a potential chemopreventive agent.